Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

Akki
Please answer the Question
Why did Platinum and AEF invest in Per
to the tune of $5 million..

Who is to blame ?
Why couldn’t Per go directly to a phase 3 in DMD.study
Spent 4 years eroding shareholder value by designing and developing a phase 3 study Per could not afford.
Yes ! Thats why my predictions of $1 did not come to fruition.
This was seen by the current Board and thankfully they adjusted the study to get a readout at the end of 6 months.
Which in my opinion was the smart thing to do.
Not only will it alert the FDA but it will attract Big Pharma with the robust data generated…
So all the negative investors Sell or wait until Nov 24 to be granted substantial ROI.